Table II.
Basic characteristics of patients with AML and control subjects.
| Characteristic | AML (n=158) | Control (n=146) | P-value |
|---|---|---|---|
| Sex, female/male | 72/86 | 66/80 | 0.949 |
| Age, yearsa | 42.37±16.00 | 41.63±12.56 | 0.651 |
| Fusion gene, n (%) | |||
| AML1-ETO | 20 (12.7) | ||
| CBFβ/MYH | 9 (5.7) | ||
| PML-RARα | 17(10.8) | ||
| Peripheral bloodb | |||
| Hb, g/l | 76.00 (60.50–100.50) | ||
| WBC, ×109 cells/l | 13.75 (4.23–55.70) | ||
| PLT, ×109 cells/l | 23.00 (12.00–47.50) | ||
| Hypocytosis, n (%) | 26 (16.5) | ||
| HLAL, n (%) | 23 (14.6) | ||
| Bone marrow blast cell, %b | 73.00 (45.00–90.00) |
a
Data are presented as the mean ± standard deviation.
b
Data are presented as the median (interquartile range). HLAL, hyperleukocytic acute leukemia; AML, acute myeloid leukemia; ETO, eight-twenty-one oncoprotein; CBFβ, core-binding transcription factor β; MYH, myosin heavy chain; PML, promyelocytic leukemia; RARα, retinoic acid α receptor; WBC, white blood cell; PLT, platelet; Hb, hemoglobin; SD, standard deviation.